Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7568282 for early symptomatic Alzheimer's disease
2026-526158-14-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Nov 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing RO7568282 with Placebo comparator (2 arms). Primary endpoint: Change from baseline to Week 72 in CDR-SB. Planned start Nov 2026; status: authorised.
02
Drugs
RO7568282
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2026-526158-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526158-14-00.